World Lung Cancer Day: Four Breakthroughs Worth Watching in 2026

As World Lung Cancer Day approaches, it’s an opportunity to reflect not only on the challenges that remain, but also on how quickly lung cancer research is advancing. Lung cancer remains the leading cause of cancer-related death worldwide. In the US alone, an estimated 229,410 people will be diagnosed and nearly 125,000 will die from the disease in 2026, accounting for roughly one in five cancer deaths.

But 2026 has also been a year of remarkable progress. This year has brought major clinical trial results, new FDA approvals, and important long-term data that are reshaping how lung cancer is treated across multiple stages of disease.

Here are the developments that stood out this year.

FDA approvals are expanding treatment options

Scientific breakthroughs only change patient care once they become available in clinical practice. In 2026, the FDA approved two new targeted therapies for lung cancer, further expanding treatment options for patients with specific genomic alterations.

Zongertinib (Hernexeos) received accelerated approval for previously untreated HER2-mutant NSCLC, with an objective response rate of 76% in clinical trials. The drug also became the second therapy approved through the FDA’s National Priority Voucher pilot program, completing regulatory review in just 44 days.

The FDA also approved zidesamtinib (Jideytro) for previously treated ROS1-positive NSCLC, providing a new treatment option for another rare molecular subtype. Together, these approvals reflect how precision oncology continues to deliver new therapies for patients whose tumors are driven by specific genetic alterations.

Immunotherapy may become available to more patients

Immunotherapy continues to evolve beyond today’s standards, with new approaches showing the potential to benefit more patients and deliver better outcomes.

The Phase II ROSETTA Lung-02 trial showed that the investigational bispecific antibody pumitamig, which targets both PD-L1 and VEGF-A, achieved a 70% overall response rate and 100% disease control rate in previously untreated advanced NSCLC, regardless of PD-L1 status. If these results are confirmed in the ongoing Phase III trial, many more patients could become eligible for first-line immunotherapy.

Another major milestone came from the Phase III HARMONi-6 trial. It became the first study to demonstrate a significant overall survival benefit over a standard PD-1 inhibitor plus chemotherapy regimen in first-line squamous NSCLC. Patients treated with ivonescimab plus chemotherapy achieved a median overall survival of 27.9 months, compared with 23.7 months for tislelizumab plus chemotherapy, reducing the risk of death by 34%.  These results suggest that dual targeting of PD-1 and VEGF may represent the next major advance in first-line immunotherapy for lung cancer.

Targeted therapies are redefining long-term outcomes

Seven-year follow-up from the CROWN trial showed that 55% of patients receiving lorlatinib remained progression-free, compared with only 3% receiving crizotinib.

Few studies in lung cancer can demonstrate benefits over such an extended follow-up. These results highlight how targeted therapies are changing expectations for patients with ALK-positive NSCLC, offering the possibility of long-lasting disease control rather than short-term response alone.

Treatment is moving earlier

One of the biggest shifts in lung cancer is not just the development of new targeted therapies, but when they are used.

Results from the Phase III LIBRETTO-432 trial showed that patients with RET fusion-positive early-stage NSCLC who received selpercatinib after surgery achieved a 2-year event-free survival rate of 92%, compared with 61% for placebo. Together with earlier advances for EGFR- and ALK-positive disease, these findings reinforce a broader trend: precision medicine is increasingly being used to prevent recurrence, not just treat advanced disease.

A New Era in Lung Cancer Care

These developments signal a year of meaningful progress against the world’s leading cause of cancer death, from newly approved therapies for rare molecular subtypes, to next-generation bispecific immunotherapies, to targeted treatments that are now proving their durability over seven years and their value even before disease recurs. Taken together, they point toward a future where more patients are matched to the right therapy earlier, with better long-term outcomes.

At Cromos Pharma, we are committed to driving innovation in oncology research by providing comprehensive clinical trial solutions, from early-phase development to late-stage regulatory approval.

If your company is exploring cutting-edge lung cancer therapies, we invite you to collaborate with Cromos Pharma. Let’s work together to accelerate life-changing treatments for lung cancer patients worldwide.

📩 Contact us at inquiry@cromospharma.com to learn more